Accessibility Menu
Azitra logo

Azitra(NYSEMKT) AZTR

Market Cap$10.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-100%
5 YearN/A
1 Year-84%
1 Month+32%
$0.17
-2.04%
-0.00Today
After hours$0.17-$0.00 (-0.81%)
Azitra last closing stock price
MetricPriceDate
Last closeUSD 0.182026-08-31
Azitra stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+16.36%USD 0.152026-08-24
1 month+31.88%USD 0.132026-07-31
3 month-18.98%USD 0.222026-06-02
Year to date-33.91%USD 0.262025-12-31
1 year-83.64%USD 1.072025-08-29
3 year-99.96%USD 435.562023-09-01
Since inception-99.98%USD 987.012023-06-16

Azitra Financials at a Glance

Market Cap

$10.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.27M

EPS (TTM)

-$1.31

P/E Ratio

-0.14

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.17

Volume

645,515.234

Open

$0.17

Previous Close

$0.18

Daily Range

$0.17 - $0.18

52-Week Range

$0.10 - $1.09

Estimated Earnings Date

Nov 11, 2026

AZTR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Azitra

Azitra develops new treatments for rare skin diseases using engineered bacteria and proteins. Its products aim to help people with severe skin conditions, such as Netherton syndrome and ichthyosis vulgaris. The company focuses on therapies for patients who have limited options today.

Skin Deep Solutions: Products and Services

  • ATR-12 (Netherton syndrome): Genetically modified bacteria for a rare, inherited skin disorder; 0% of revenue (pre-commercial).
  • ATR-04 (Cancer rash): Engineered bacteria to treat rashes from cancer therapy; 0% of revenue (pre-commercial).
  • ATR-01 (Ichthyosis vulgaris): Engineered human protein for a genetic skin disease; 0% of revenue (pre-commercial).
  • Microbial Library: Collection of 1,500 bacterial strains for research; supports product development, not sold directly.
  • AI/ML Platform: Uses artificial intelligence to identify and engineer bacteria for skin therapies; supports R&D, not a revenue source.

Growing Pains and Gains: Expansion Moves

  • IPO in June 2023 raised $6.0 million.
  • Follow-on offerings in 2024 and 2025 raised over $15 million combined.
  • Equity line of credit with Alumni Capital LP in April 2025, up to $20 million available.
  • Exclusive technology license from Fred Hutchinson Cancer Center for advanced genetic engineering.
  • Research partnerships with Carnegie Mellon University, Yale University, and Duke University.

What Makes Azitra Stand Out

Azitra combines a large bacterial strain library with artificial intelligence to create new skin therapies. Its exclusive technology allows genetic engineering of bacteria that are hard to modify. The company targets rare skin diseases, often overlooked by larger firms.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2024.
  • Net loss was $2.89 million in Q2 2025, up 10% year-on-year.
  • Cash used in operations was $5.89 million for six months ended June 2025.
  • Cash and equivalents fell to $1.05 million as of June 30, 2025.
  • Accumulated deficit reached $63.5 million by June 2025, with no product sales yet.

Bottom Line

Azitra is an early-stage biotech focused on rare skin diseases with no commercial products yet. The company relies on innovation and partnerships but faces ongoing financial and operational challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

Francisco D. Salva

Website

www.azitrainc.com

Headquarters

Branford, CT 06405, US

AZTR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-205.45%

Return on Capital

-259.67%

Return on Assets

-137.65%

Earnings Yield

-7.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.60M

Volume

645.52K

Avg. Volume

12.19M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$12.35M

EBITDA

-$5.22M

Operating Cash Flow

-$11.11M

Capital Expenditure

-$179.92K

Free Cash Flow

-$11.29M

Cash & ST Invst.

$6.73M

Total Debt

$410.05K

Azitra Performance Analysis

Azitra annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 284,000158.2%
20232023-12-31USD 686,000141.5%
20242024-12-31USD 7,500-98.9%
20252025-12-31USD 0N/A
Azitra sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Azitra annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -222.3314.9%
20232023-12-31USD -208.74-6.1%
20242024-12-31USD -15.78-92.4%
20252025-12-31USD -2.25-85.8%
Azitra sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3043.2%
Q42025-12-3168.7%
Q12026-03-31-19.0%
Q22026-06-3032.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$10.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$824.68K

N/A

Employees

13

N/A

Net Income

-$3.35M

-15.9%

EBITDA

$3.35M

+220.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.73M

+543.4%

Total Debt

$410.05K

-29.0%

Accounts Receivable

$144.73K

+84.6%

Inventory

$0.00

N/A

Long Term Debt

$51.00K

-81.4%

Short Term Debt

$359.06K

+18.4%

Return on Assets

-1.38%

N/A

Return on Invested Capital

-1.67%

N/A

Free Cash Flow

-$3.33M

-16.8%

Operating Cash Flow

-$3.29M

-16.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JSPRJasper Therapeutics, Inc.
$0.71+1.67%
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
REVBRevelation Biosciences, Inc.
$1.00-4.76%
ONCOOnconetix, Inc.
$0.63+2.37%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About AZTR

What is the current price of Azitra?

Azitra is trading at $0.18 per share.

What is the 52-week range for Azitra?

Over the past 52 weeks, Azitra has traded between $0.10 and $1.09.

How much debt does Azitra have?

As of the most recent reporting period, Azitra reported total debt of $410.05K.

How much cash does Azitra have on hand?

Azitra reported $6.73M in cash and cash equivalents in its most recent financial results.

What is Azitra’s dividend yield?

Azitra does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services